Newsletter

SK Biopharmaceuticals, 2Q deficit decreased… Possible turnaround in 4Q [NH투자증권]

[사진=SK바이오팜] NH Investment & Securities estimated on the 10th that the deficit of SK Biopharmaceuticals would decrease in the second quarter of this year. We maintain our Buy rating and target price of 105,000 won, respectively. NH Investment & Securities predicted that SK Biopharmaceuticals’ second-quarter sales would increase by 55% year-on-year to 82.7 billion won, […]